WEKO3
アイテム
Comparison of Dasatinib- and Imatinib-Related Cardiotoxic Adverse Events in Japanese Patients With Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor
http://hdl.handle.net/10069/00041948
http://hdl.handle.net/10069/0004194874441e51-5273-44d2-bca0-2d69446b371a
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ISYK1422_Motokawa.pdf (398.5 kB)
|
|
| Item type | 学位論文 / Thesis or Dissertation(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2023-01-06 | |||||||
| タイトル | ||||||||
| タイトル | Comparison of Dasatinib- and Imatinib-Related Cardiotoxic Adverse Events in Japanese Patients With Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor | |||||||
| 言語 | en | |||||||
| 言語 | ||||||||
| 言語 | eng | |||||||
| キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | Cardiotoxicity | |||||||
| キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | Congestive heart failure | |||||||
| キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | Pleural effusion | |||||||
| キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | Pulmonary hypertension | |||||||
| キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | QT prolongation | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||||
| 資源タイプ | doctoral thesis | |||||||
| アクセス権 | ||||||||
| アクセス権 | open access | |||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||
| 著者 |
本川, 哲史
× 本川, 哲史
|
|||||||
| 著者別名 | ||||||||
| 識別子Scheme | WEKO | |||||||
| 識別子 | 123809 | |||||||
| 姓名 | Motokawa, Tetsufumi | |||||||
| 抄録 | ||||||||
| 内容記述タイプ | Abstract | |||||||
| 内容記述 | Background: Despite the beneficial effects ofBCR-ABL1tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML), they may also cause adverse events (AEs), especially cardiovascular toxicity. The incidence of TKI-induced AEs may vary among ethnic groups, and there is little specific information for Japanese patients. Methods and Results: Sixty-nine consecutive patients who were started on treatment with dasatinib (n=25) or imatinib (n=44) for CML or gastrointestinal stromal tumor (GIST) between December 2008 and December 2019 were retrospectively recruited to the study. We determined the prevalence of AEs through October 2020 and compared the incidence of AEs between the 2 drugs. Baseline characteristics were comparable between the 2 groups. However, compared with the imatinib-treated group, the dasatinib-treated group had a higher incidence of congestive heart failure (CHF; 20.0% vs. 2.3%; P=0.04), pleural effusion (48% vs. 20.5%; P=0.03), pericardial effusion (24% vs. 4.6%; P=0.02), QT prolongation (4 vs. 0 patients; P=0.02), and pulmonary hypertension (3 vs. 0 patients; P=0.04). In the dasatinib-treated group, CHF tended to be associated with tricuspid valve regurgitation pressure gradient, and pleural effusion was observed in all patients. All-cause mortality and other cardiovascular events did not differ significantly between the 2 groups. Conclusions: Cardiotoxic AEs occurred more frequently in Japanese patients with CML and GIST treated with dasatinib than imatinib. |
|||||||
| 内容記述 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | 長崎大学学位論文 学位記番号:博(医歯薬)甲第1422号 学位授与年月日:令和4年3月18日 | |||||||
| 内容記述 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | Author: Tetsufumi Motokawa, Satoshi Ikeda, Yuki Ueno, Masamichi Eguchi, Takako Minami, Hiroaki Kawano, Kazuma Kobayashi, Yoshitaka Imaizumi, Koji Maemura | |||||||
| 内容記述 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | Citation: Circulation Reports, 4(1), pp. 1-8; 2022 | |||||||
| 書誌情報 |
Circulation Reports 巻 4, 号 1, p. 1-8, 発行日 2022-03-18 |
|||||||
| EISSN | ||||||||
| 収録物識別子タイプ | ISSN | |||||||
| 収録物識別子 | 2434-0790 | |||||||
| DOI | ||||||||
| 識別子タイプ | DOI | |||||||
| 関連識別子 | 10.1253/circrep.CR-21-0140 | |||||||
| 権利 | ||||||||
| 権利情報 | © 2022, THE JAPANESE CIRCULATION SOCIETY | |||||||
| 著者版フラグ | ||||||||
| 出版タイプ | VoR | |||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
| その他のタイトル | ||||||||
| その他のタイトル | 慢性骨髄性白血病および消化管間質腫瘍(GIST)の日本人患者におけるダサチニブおよびイマチニブに関連する心毒性有害事象の比較 | |||||||
| 出版者 | ||||||||
| 出版者 | The Japanese Circulation Society | |||||||
| 関係URI | ||||||||
| 識別子タイプ | HDL | |||||||
| 関連識別子 | http://hdl.handle.net/10069/00041425 | |||||||
| 学位名 | ||||||||
| 学位名 | 博士(医学) | |||||||
| 学位授与機関 | ||||||||
| 学位授与機関識別子Scheme | kakenhi | |||||||
| 学位授与機関識別子 | 17301 | |||||||
| 学位授与機関名 | Nagasaki University (長崎大学) | |||||||
| 学位授与年月日 | ||||||||
| 学位授与年月日 | 2022-03-18 | |||||||
| 学位授与番号 | ||||||||
| 学位授与番号 | 甲医歯薬第1422号 | |||||||
| 学位の種類 | ||||||||
| 値 | 課程博士 | |||||||
| 引用 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | Nagasaki University (長崎大学), 博士(医学) (2022-03-18) | |||||||
